FDA局长Marty Makary博士在经历了13个月动荡的任期后辞职，其间伴随着组织动荡和争议。他旨在简化药物审批和提高透明度的倡议因可能用政治利益压倒科学原则而受到批评。该机构经历了显著的人员流失和领导层变动，给Makary的政策变动以及其继任者的任命带来了不确定性。 AI
影响 尚不清楚AI是否用于药物评估；Makary的离职给监管简化工作带来了不确定性。
排序理由 一位备受瞩目的政府机构负责人因争议性任期而辞职。[lever_c_demoted from significant: ic=4 ai=0.4]
AI 生成摘要 · Google Gemini · 来自 4 个来源。 我们如何撰写摘要 →
During a tumultuous 13-month tenure at the FDA, Makary pursued a wide range of ambitious initiatives. Going forward, their status under the next commissioner is unclear.
He's lasted longer than some previous heads, including one that announced his retirement after just three weeks on the job.
<p>Marty Makary's <a href="https://www.axios.com/2026/05/12/makary-out-fda-chief-turmoil" target="_blank">departure</a> from the Food and Drug Administration may remove one of the Trump administration's lightning rods for controversy.</p><ul><li>But it won't solve the organizatio…
<p>Food and Drug Administration Commissioner <a href="https://www.axios.com/2026/05/11/fda-cliffhanger-makary-trump-administration" target="_blank">Marty Makary</a> is stepping down after a turbulent 13-month term marked by organizational upheaval, controversies over drug approva…